{"schema_version":"secwatch.filing_event.v1","accession":"0000318154-24-000018","form_type":"8-K","ticker":"AMGN","cik":"0000318154","company_name":"AMGEN INC","filed_at":"2024-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.534862+00:00","generated_at":"2026-06-03T01:01:30.264532+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Amgen Q1 2024 revenue up 22% to $7.4B; GAAP EPS loss of $0.21 on BeiGene mark-to-market loss","bullets":["Total revenue $7.4B (+22% YoY); product sales grew 22% driven by 25% volume growth; Horizon contributed $914M.","GAAP EPS loss of $0.21 vs $5.28 gain YoY, driven by mark-to-market loss on BeiGene equity investment.","Non-GAAP EPS $3.96 (-1% YoY); non-GAAP operating income $3.1B (+11% from $2.8B).","Ten products delivered double-digit volume growth including Repatha, TEZSPIRE, EVENITY, BLINCYTO, TAVNEOS.","Free cash flow $0.5B vs $0.7B; decrease from $800M tax deposit partially offset by working capital timing."],"urls":{"canonical":"https://secwatch.observer/filing/0000318154-24-000018","json":"https://secwatch.observer/filing/0000318154-24-000018.json","markdown":"https://secwatch.observer/filing/0000318154-24-000018.md","text":"https://secwatch.observer/filing/0000318154-24-000018.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/318154/000031815424000018/0000318154-24-000018-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/318154/000031815424000018/amgn-20240502.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T01:01:30.264532+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e65e5d24591588030773fad2ebde2e826ec0f934","claim":"AMGEN INC reported first quarter 2024 results: revenue $7.4 billion, EPS $3.96.","evidence_excerpt":"For the first quarter, total revenues increased 22% to $7.4 billion in comparison to the first quarter of 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/318154/000031815424000018/0000318154-24-000018-index.htm","confidence":0.92,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter 2024"},{"label":"Revenue","value":"$7.4 billion"},{"label":"EPS","value":"$3.96"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}